- £184.59bn
- £203.88bn
- $54.07bn
- 85
- 18
- 85
- 73
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the US for bladder cancer
AnnouncementREG - AstraZeneca PLC - Calquence recommended for EU approval in 1L MCL
AnnouncementREG - AstraZeneca PLC - AZN invests $2.5bn in Beijing R&D & manufacturing
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire EsoBiotec
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for limited-stage SCLC
AnnouncementREG - AstraZeneca PLC - Eneboparatide Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi improved EFS in early-stage gastric cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval for AEGEAN
AnnouncementREG - AstraZeneca PLC - Enhertu recommended in EU in post-ET breast cancer
AnnouncementREG - AstraZeneca PLC - Camizestrant improved PFS in 1L HR+ breast cancer
AnnouncementREG - Redx Pharma Limited - Phase 1 Data on RXC008 Presented at ECCO
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
Announcement